How would you manage subsequent treatment for a patient with metastatic ER+HER2- breast cancer that develops pneumonitis on a CDK4/6 inhibitor but had an excellent response to therapy?

Topics: Breast Cancer • Medical Oncology • NCI-CCC Tumor Board Question • UCLA • HR+ • NCI-CCC Breast Tumor Board Question

Would you change to a different CDK4/6 inhibitor or avoid the entire class of drugs?

Answer from: Medical Oncologist at Academic Institution

One of our fellows and I conducted a lit search on this topic several months ago, and then again (briefly) today. There is not much literature to support evidence-based decision making, as the 3 available CDK4/6 inhibitors (palbociclib, abemacicilib, and ribociclib) all have pneumonitis as a reporte...

Comments

Medical Oncologist at St Lukes Cancer Care Assocs
I will be reluctant to switch or re-challenge.

Related Questions